ArticlePDF Available

Meta-analyses: What is heterogeneity?

Authors:

Abstract

Researchers undertook a meta-analysis to evaluate the effectiveness of multifactorial assessment and intervention programmes in preventing falls and injuries among older people. Randomised or quasi-randomised trials that evaluated interventions to prevent falls and injuries were included. The intervention had to be delivered to individual patients, not at a community or population level. It also had to be service based in an emergency department, primary care, or the community. Control groups could receive standard care or no fall prevention. The outcomes included the number of fallers and fall related injuries.1In total 19 trials were identified. Of these, eight reported fall related injuries. When combined across trials, the risk for fall related injuries was reduced after the intervention compared with the control, but not significantly (relative risk 0.90, 95% confidence interval 0.68 to 1.20). Tests of statistical heterogeneity for the meta-analysis of fall related injuries gave the following results: χ2=15.77, degrees of freedom=7, P=0.03 (Cochran’s Q test), I2=55.6% (Higgins’s I2 test statistic). Subgroup analyses using a test of interaction based on Cochran’s Q test were subsequently performed. The resulting P values were: P=0.75 for site of delivery (hospital v community); P=0.75 for whether a doctor was included in the team (yes v no); and P=0.52 for whether trial participants had been selected because they were at high risk of falls (yes v no).The study concluded that there was limited evidence that multifactorial fall prevention programmes in primary care, community, or emergency care settings were effective in reducing the number of fallers or fall related injuries.Which of the following statements, if any, are true for the meta-analysis of fall related injuries?a) The presence of statistical heterogeneity would be indicative of variation between trials in the magnitude or direction of the sample estimates of the relative risk of fall related injuriesb) The result of Cochran’s Q test indicated that heterogeneity existed between the sample estimatesc) Higgins’s I2 test statistic indicated that homogeneity existed between the sample estimatesd) Any statistical heterogeneity in the overall meta-analysis of fall related injuries was not explained by the subgroup analysesAnswersStatements a, b, and d are true, whereas c is false.A total of eight trials reported fall related injuries. For each trial a sample estimate of the population parameter of the relative risk of fall related injuries after multifactorial assessment and intervention programmes compared with control was obtained. The aim of the meta-analysis was to combine the sample estimates from the eight trials and provide a single estimate of the population parameter. By combining the sample estimates, the meta-analysis reduced the evidence to a manageable quantity. The figure⇓ shows the forest plot for the meta-analysis. The interpretation of a forest plot has been described in a previous question.2
STATISTICAL QUESTION
Meta-analyses: what is heterogeneity?
Philip Sedgwick reader in medical statistics and medical education
Institute for Medical and Biomedical Education, St George’s, University of London, London, UK
Researchers undertook a meta-analysis to evaluate the
effectiveness of multifactorial assessment and intervention
programmes in preventing falls and injuries among older people.
Randomised or quasi-randomised trials that evaluated
interventions to prevent falls and injuries were included. The
intervention had to be delivered to individual patients, not at a
community or population level. It also had to be service based
in an emergency department, primary care, or the community.
Control groups could receive standard care or no fall prevention.
The outcomes included the number of fallers and fall related
injuries.1
In total 19 trials were identified. Of these, eight reported fall
related injuries. When combined across trials, the risk for fall
related injuries was reduced after the intervention compared
with the control, but not significantly (relative risk 0.90, 95%
confidence interval 0.68 to 1.20). Tests of statistical
heterogeneity for the meta-analysis of fall related injuries gave
the following results: χ2=15.77, degrees of freedom=7, P=0.03
(Cochran’s Q test), I2=55.6% (Higgins’s I2test statistic).
Subgroup analyses using a test of interaction based on Cochran’s
Q test were subsequently performed. The resulting P values
were: P=0.75 for site of delivery (hospital vcommunity); P=0.75
for whether a doctor was included in the team (yes vno); and
P=0.52 for whether trial participants had been selected because
they were at high risk of falls (yes vno).
The study concluded that there was limited evidence that
multifactorial fall prevention programmes in primary care,
community, or emergency care settings were effective in
reducing the number of fallers or fall related injuries.
Which of the following statements, if any, are true for the
meta-analysis of fall related injuries?
a) The presence of statistical heterogeneity would be
indicative of variation between trials in the magnitude or
direction of the sample estimates of the relative risk of fall
related injuries
b) The result of Cochran’s Q test indicated that heterogeneity
existed between the sample estimates
c) Higgins’s I2test statistic indicated that homogeneity
existed between the sample estimates
d) Any statistical heterogeneity in the overall meta-analysis
of fall related injuries was not explained by the subgroup
analyses
Answers
Statements a,b, and dare true, whereas cis false.
A total of eight trials reported fall related injuries. For each trial
a sample estimate of the population parameter of the relative
risk of fall related injuries after multifactorial assessment and
intervention programmes compared with control was obtained.
The aim of the meta-analysis was to combine the sample
estimates from the eight trials and provide a single estimate of
the population parameter. By combining the sample estimates,
the meta-analysis reduced the evidence to a manageable
quantity. The figure shows the forest plot for the meta-analysis.
The interpretation of a forest plot has been described in a
previous question.2
Forest plot of the sample estimates of the relative risk of
fall related injuries after multifactorial assessment and
intervention programmes compared with the control
The combined relative risk of fall related injuries after the
intervention versus the control was 0.90 (95% confidence
interval: 0.68 to 1.20). Therefore, although the risk of fall related
injuries was reduced after the intervention, the difference was
not significant. It was essential that the meta-analysis
incorporated a statistical test of heterogeneity. The purpose of
this test was to assess the extent of variation between the sample
estimates. Heterogeneity would exist if the sample estimates
for the population relative risk were of different magnitudes or
had the opposite direction of effect (ais true). Conversely, if
p.sedgwick@sgul.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h1435 doi: 10.1136/bmj.h1435 (Published 16 March 2015) Page 1 of 3
Endgames
ENDGAMES
homogeneity existed the estimates would be of a similar
magnitude and direction. If heterogeneity existed, it would
influence how the total overall estimate was calculated, as
described below. Furthermore, it would be sensible to explore
the potential sources of heterogeneity. For example,
heterogeneity would occur if the effect of the intervention
differed between the sites where it was delivered (hospital v
community). If so, it would be useful to estimate the effect of
the intervention separately for each of the site of intervention
subgroups. Otherwise, the results of the meta-analysis might be
misleading regarding the effectiveness of the intervention and
might be detrimental to future patient care.
The most routinely used tests for statistical heterogeneity are
Cochran’s Q test and Higgins’s I2test statistic. Cochran’s Q is
the traditional test of heterogeneity and is based on the χ2test,
which has been described in a previous question.3The statistical
test of heterogeneity using Cochran’s Q test is carried out in a
similar way to traditional statistical hypothesis testing, with a
null hypothesis and an alternative hypothesis. The null
hypothesis states that homogeneity exists between the sample
estimates of the population parameter across the trials, and any
variation between them is no more than would be expected when
taking samples from the same population—that is, any variation
between them is a result of sampling error. The alternative
hypothesis states that heterogeneity exists between the sample
estimates. The results for the test of heterogeneity for the
meta-analysis of fall related injuries are displayed towards the
bottom of the forest plot in the line “Test for heterogeneity:
χ2=15.77, df=7, P=0.03, I2=55.6%.” The first three statistics are
the χ2test statistic, degrees of freedom (df), and P value resulting
from Cochran’s Q test of the statistical hypotheses described
above. The I2statistic refers to Higgins’s I2test described below.
The resulting P value for Cochran’s Q test was 0.03, and because
it was smaller than the traditional critical level of significance
of 0.05 (5%), the null hypothesis was rejected in favour of the
alternative, with the conclusion that heterogeneity existed
between the sample estimates (bis true).
Cochran’s Q test is not very accurate; it is conservative and
often fails to detect heterogeneity in the sample estimates.
Therefore, a critical level of significance of 0.10 (10%) is often
chosen rather than the traditional one of 0.05 (5%). Because of
the lack of accuracy of Cochran’s Q test, Higgins’s I2test
statistic is often used as an additional test of heterogeneity.
Higgins’s I2test statistic represents the proportion of variation
between the sample estimates that is due to heterogeneity rather
than to sampling error. Values can range from 0% to 100%,
with 0% indicating that statistical homogeneity exists and 100%
indicating that statistical heterogeneity exists. It has been
suggested that the adjectives low, moderate, and high
(heterogeneity) be assigned to I2values of 25%, 50%, and 75%.
In general, significant heterogeneity is considered to be present
if I2is 50% or more. In the above meta-analysis, I2was reported
as 55.6%, indicating the presence of significant heterogeneity
(cis false) and confirming the result of Cochran’s Q test.
The test of statistical heterogeneity influenced how the combined
overall estimate of the relative risk for fall related injuries after
the intervention compared with the control was obtained. The
presence of heterogeneity between the sample estimates
indicated that “random effects” methods should be used to derive
the combined overall estimate of the treatment effect. If
homogeneity had existed, “fixed effects” methods would have
been used. A meta-analysis incorporating random effects
methodology produces a wider confidence interval for the
combined overall effect than one in which fixed effects
methodology is used, resulting in a less accurate estimate of the
effect of the intervention. The reduced accuracy of the combined
overall effect of the intervention reflected the heterogeneity
between the sample estimates.
The researchers undertook a subgroup analysis to investigate
the heterogeneity between the sample estimates. The aim was
to establish whether the heterogeneity between the eight trials
in the sample estimates of the relative risk of fall related injuries
could be explained by differences between the trials—for
example, in how the intervention was delivered or participants
recruited. If so, the effects of the intervention might vary
according to how the intervention is delivered or between
subgroups of patients, which would have implications for future
care. The researchers chose the factors that were thought to be
important in explaining the observed heterogeneity between the
sample estimates. These subgroups were based on three
factors—site of delivery (hospital vcommunity), whether a
doctor was included in the team (yes vno), and whether trial
participants had been selected because they were at high risk
of falls (yes vno).
For each factor subgroup, a separate meta-analysis of injury
related falls was performed and a subtotal estimate for the effect
of the intervention derived by combining the sample estimates
across trials within the subgroup. A test of heterogeneity was
undertaken for the meta-analysis within each subgroup, although
the results were not presented. The subtotal estimates for the
effects of the intervention and tests of heterogeneity can be
compared between subgroups for a factor, although if done
visually this should be done informally only. In particular, the
lack of statistical significance for the test of heterogeneity within
each subgroup does not indicate that the subgroups within the
factor explain the statistical heterogeneity observed overall. It
may be misleading to compare the results of the tests of
statistical heterogeneity between factor subgroups because the
subgroups may not have sufficient statistical power with respect
to the numbers of trials and participants to detect heterogeneity.
To formally investigate heterogeneity across the subgroups of
a factor, the subtotal estimates for the effects of the intervention
in the subgroups were compared by a test of interaction. For
example, the test of interaction for the factor site of delivery of
intervention (hospital vcommunity) investigated whether the
effect of the intervention on the risk of fall related injuries varied
between the subgroups. Interaction is sometimes referred to as
effect modification. In a meta-analysis, interaction is
investigated using Cochran’s Q test or Higgins’ I2, or both.
These tests involve comparing the subtotal estimates between
the subgroups. Cochran’s Q test provides a test of the null
hypothesis that homogeneity exists between the subgroups in
the subtotal estimates of the population parameter—that is, any
variation between the subgroups is no more than would be
expected as a result of sampling error. Higgins’s I2test statistic
measures the proportion of total variation between the subgroups
in the subtotal estimates that is due to heterogeneity rather than
to sampling error. The test of interaction contrasts with the test
of heterogeneity in the meta-analysis that combines all the trials,
where Cochran’s Q and Higgins’s I2were used to compare the
sample estimates of the treatment effect across all of the trials.
A test of interaction was undertaken for each factor—site of
delivery, whether a doctor was included in the team, and whether
participants were selected because they were at high risk of
falls. For each factor, the researchers performed Cochran’s Q
test to test for interaction between the subgroups. The results
of the test of interaction were χ2=0.1, P=0.75 for the site of
delivery (hospital vcommunity); χ2=0.1, P=0.75 for whether a
doctor was included in the team (yes vno); and χ2=0.42, P=0.52
for whether trial participants had been selected because they
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h1435 doi: 10.1136/bmj.h1435 (Published 16 March 2015) Page 2 of 3
ENDGAMES
were at high risk of falls (yes vno). In none of these tests of
interaction was the P value less than the traditional critical level
of significance of 0.05 (5%). Therefore, the statistical
heterogeneity in the overall meta-analysis of fall related injuries
was not explained by the subgroup analyses (dis true). The
researchers commented that because the studies were carried
out in several countries, differences between the populations or
healthcare systems might have contributed to the heterogeneity.
Methodological differences between trials may also contribute
to statistical heterogeneity. In particular, the meta-analysis above
included trials that were randomised or quasi-randomised and
therefore of variable methodological quality. A
quasi-randomised trial uses methods of allocating participants
to treatment groups that are not truly random—for example,
alternate allocation.
Caution is needed when interpreting findings from subgroup
analyses that use tests of interaction. The results may be
misleading because the analyses are observational and not based
on comparisons between randomised groups of patients, and
therefore prone to confounding.
Competing interests: None declared.
1 Gates S, Fisher JD, Cooke MW, et al. Multifactorial assessment and targeted intervention
for preventing falls and injuries among older people in community and emergency care
settings: systematic review and meta-analysis. BMJ 2008;336:130.
2 Sedgwick P. How to read a forest plot. BMJ 2012;345:e8335.
3Sedgwick P. Statistical tests for independent groups: categorical data. BMJ 2012;344:e344.
Cite this as: BMJ 2015;350:h1435
© BMJ Publishing Group Ltd 2015
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h1435 doi: 10.1136/bmj.h1435 (Published 16 March 2015) Page 3 of 3
ENDGAMES
... Random-effects meta-analyses were run to compute pooled effect sizes (Cohen's d) and confidence intervals. Past research indicates that random-effects models are more conservative and should be preferred over fixed-effects models as it allows for calculation of measures of heterogeneity (Cochran's Q) across studies (Sedgwick, 2015) for each meta-analysis (Hunter & Schmidt, 2000). To test for significant differences in effect sizes across groups, an observation on whether the confidence intervals overlapped was carried out (where non-overlap was interpreted as a significant difference between effect sizes). ...
Article
Full-text available
Background: Cognitive Behavioural Therapy (CBT) has been proven to be effective for anxiety and depression in children and young people (CYP). Over the past 20 years there have been several attempts at delivering CBT through apps, online software, videogames, but also with a therapist via phone or videoconferencing platforms, with promising results for the “technology-assisted” versions. However, most research, have compared online CBT to waiting lists, and not many studies looked at the effectiveness of face-to-face (f2f) CBT versus technology-assisted CBT. Methods: Adopting the PRISMA guidelines, we evaluated 1849 citations and identified 10 eligible studies. Studies were identified through the Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO, PubMed/MEDLINE, Web of Science, and Scopus. Results: Ten studies met our inclusion criteria. The studies included a variety of technology-assisted forms of CBT, including videoconferencing and online CBT. Of these, seven looked at the effectiveness of technology-assisted CBT for anxiety in CYP, and seven looked at depression. The meta-analyses had low heterogeneity and showed that technology-assisted CBT was non-inferior to f2f CBT for anxiety and depression in CYP ( d = 0.06 and 0.12 respectively). Conclusions: Technology-assisted CBT may be a valid alternative for the treatment of anxiety and depression in CYP. Future studies should consider what specific delivery modalities are most cost-effective.
... Significant heterogeneity was observed in the 22 studies (Fig. 1). Heterogeneity, assessment for which is regarded as mandatory in meta-analysis [95], invalidates the meta-analysis performed by blanket tallying of the results [97,98]. Confounders are responsible for heterogeneity [95]. ...
Article
Full-text available
Sporadic fundic gland polyps (FGPs) progress, albeit rarely, to dysplasia and cancer. Two meta-analyses, including 8 and 11 studies, concluded that proton pump inhibitors (PPIs) were associated with FGPs. Intervention is considered unnecessary when FGPs have a background of PPIs use. Both meta-analyses, however, disregarded known confounders: age, sex, endoscopy indications, study design (prospective or retrospective), duration of PPI use, and H. pylori infection. Confounders are known to invalidate meta-analyses. We followed PRIXMA guidelines and searched the literature for studies on FGPs in PPI-users and PPI-nonusers. In the 22 studies searched, we compared FGPs in PPI-users ( n = 6534) and PPI-nonusers ( n = 41 115). Heterogeneity was significant (Cochran Q = 277.8, P < 0.0001; I ² = 92.8%), annulling meta-analysis performed by blanket tallying. To offset the above confounders, we matched PPI-users and PPI-nonusers by (a) age and sex ( n = 4300 and 29 307, respectively) and (b) their propensity scores derived from the confounders ( n = 2950 and 4729, respectively). After both matching, FGPs were not significantly different between PPI-users and PPI-nonusers [odds ratio (OR) = 1.1, P = 0.3078; OR = 0.9, P = 0.3258, respectively]. Furthermore, FGP frequency did not correlate with increasing duration of PPI use (Pearson and Spearman correlation coefficients = 0.1162, 0.0386, P < 0.6064, 0.8646, respectively); it was not significantly different between any of the duration periods of observation, namely, <10, 10–20, 20–40, >40 months, nor was it significantly different between PPI-users and PPI-nonusers within each duration period ( P > 0.05). We conclude that PPIs are not associated with FGPs, implying that a background history of PPI use is not a justification for nonintervention in the management of FGPs.
... Heterogeneity was defined as a p-value less than 0.05. We used I 2 25, 50, and 75% statistics to indicate low, moderate, and high heterogeneity [27], respectively. A meta-analysis's potential publication bias is often evaluated using Egger's and Begg's tests, with a p-value of less than 0.005 indicating the significance of the results [28]. ...
Article
Full-text available
Background Pertussis, a highly contagious, vaccine-preventable respiratory infection caused by Bordetella pertussis, is a leading global public health issue. Ethiopia is currently conducting multiple pertussis outbreak investigations, but there is a lack of comprehensive information on attack rate, case fatality rate, and infection predictors. This study aimed to measure attack rates, case fatality rates, and factors associated with pertussis outbreak. Methods This study conducted a systematic review and meta-analysis of published and unpublished studies on pertussis outbreaks in Ethiopia from 2009 to 2023, using observational study designs, using the guideline Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The study utilized databases like Science Direct, MEDLINE/ PubMed, African Journals Online, Google Scholar and registers. The data were collected using an Excel Spreadsheet and then exported to STATA version 17 for analysis. Subgroup analysis was conducted to identify potential disparities. A random effects model was used to consider heterogeneity among studies. I2 -squared test statistics were used to assess heterogeneity. The attack rate, case fatality rate, and odds ratio (OR) were presented using forest plots with a 95% confidence interval. Egger’s and Begg’s tests were used to evaluate the publication bias. Results Seven pertussis outbreak investigations with a total of 2824 cases and 18 deaths were incorporated. The pooled attack and case fatality rates were 10.78 (95% CI: 8.1–13.5) per 1000 population and 0.8% (95% CI: 0.01–1.58%), respectively. The highest and lowest attack rates were in Oromia (5.57 per 1000 population and in the Amhara region (2.61 per 1000 population), respectively. Predictor of pertussis outbreak were being unvaccinated [odds ratio (OR)=3.05, 95% CI: 1.83–4.27] and contact history [OR=3.44, 95% CI: 1.69–5.19]. Conclusion Higher and notable variations in attack and case fatality rates were reported. Being unvaccinated and having contact history were the predictors of contracting pertussis disease in Ethiopia. Enhancing routine vaccination and contact tracing efforts should be strengthened. Keywords Pertussis · Outbreak · Review · Ethiopia
... A significant heterogeneity was observed in most prevalence estimates in this meta-analysis. This was expected as it is indicative of variation between studies that commonly exists in epidemiological studies conducted in different places (Higgins, 2008;Mobarez et al., 2017;Sedgwick, 2015). ...
Article
Full-text available
Background Coxiellosis is a neglected zoonosis for occupationally exposed people in many parts of the world. Sheep and goats are two important small ruminants that act as reservoirs for human contamination; however, there is a lack of comprehensive data on the epidemiological aspects of coxiellosis in sheep and goats at regional and global levels. The aim of this study was to systematically review the available articles on seroprevalence of coxiellosis in sheep and goats and estimate the overall seroprevalence in different regions. Methods A systematic search strategy was performed in five electronic repositories for articles published until December 2021. Relevant data were extracted from the selected articles based on the inclusion criteria. A random effect meta‐analysis model was used to analyse the data. Results are presented as the prevalence of seropositivity as a percentage and 95% confidence intervals. Results The global pooled seroprevalence of coxiellosis in sheep was 17.38% (95% confidence interval [CI]: 15.59%–19.17%). Overall, the regional level pooled prevalence estimates in sheep ranged from 15.04% (95% CI: 7.68%–22.40%) to 19.14% (95% CI: 15.51%–22.77%), depending on region. The global pooled seroprevalence of coxiellosis in goats was 22.60% (95% CI: 19.54%–25.66%). Overall, the regional level pooled prevalence estimates in goats ranged from 6.33% (95% CI: 2.96%–9.71%) to 55.13% (95% CI: 49.61%–60.65%), depending on the region. The prevalence estimates also varied significantly in both sheep and goats depending on age, sex, and rearing systems of the animals (p < 0.001). Conclusion Seroprevalence of coxiellosis in both sheep and goats is considerable. Routine monitoring of the sheep and goat populations is needed to prevent spillover infection in other livestock and humans.
... Clinical heterogeneity was estimated by comparing the population, exposure/comparison, outcome definition, and other clinical features among studies. If metaanalysis is feasible, the statistical heterogeneity across the studies was further assessed using a Chi-square-based Q-test and I 2 statistics [23]. Initially, this review was intended as a meta-analysis if valid data assessing the association between genetic polymorphisms with rivaroxaban-related efficacy, safety and PK outcomes were available from sufficiently homogeneous studies. ...
Article
Full-text available
Background: Investigations into the rivaroxaban response from the perspective of genetic variation have been relatively recent and wide in scope, whereas there is no consensus on the necessity of genetic testing of rivaroxaban. Thus, this systematic review aims to thoroughly evaluate the relationship between genetic polymorphisms and rivaroxaban outcomes. Methods: The PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Chinese databases were searched to 23 October 2022. We included cohort studies reporting the pharmacogenetic correlation of rivaroxaban. Outcomes measured included efficacy (all-cause mortality, thromboembolic events and coagulation-related tests), safety (major bleeding, clinically relevant non-major bleeding [CRNMB] and any hemorrhage), and pharmacokinetic outcomes. A narrative synthesis was performed to summarize findings from individual studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the reporting guideline for Synthesis Without Meta-Analysis. Results: A total of 12 studies published between 2019 and 2022 involving 1364 patients were included. Ten, one, and six studies focused on the ABCB1, ABCG2, and CYP gene polymorphisms, respectively. Pharmacokinetic outcomes accounted for the majority of the outcomes reported (n = 11), followed by efficacy (n = 5) [including prothrombin time (PT) or international normalized ratio (n = 3), platelet inhibition rate (PIR) or platelet reactivity units (PRUs; n = 1), thromboembolic events (n = 1)], and safety (n = 5) [including major bleeding (n = 2), CRNMB (n = 2), any hemorrhage (n = 1)]. For ABCB1 gene polymorphism, the relationship between PT and ABCB1 rs1045642 was inconsistent across studies, however there was no pharmacogenetic relationship with other efficacy outcomes. Safety associations were found in ABCB1 rs4148738 and major bleeding, ABCB1 rs4148738 and CRNMB, ABCB1 rs1045642 and CRNMB, and ABCB1 rs2032582 and hemorrhage. Pharmacokinetic results were inconsistent among studies. For ABCG2 gene polymorphism, no correlation was observed between ABCG2 rs2231142 and dose-adjusted trough concentration (Cmin/D). For CYP gene polymorphisms, PIR or PRUs have a relationship with CYP2C19 rs12248560, however bleeding or pharmacokinetic effects did not show similar results. Conclusions: Currently available data are insufficient to confirm the relationship between clinical or pharmacokinetic outcomes of rivaroxaban and gene polymorphisms. Proactive strategies are advised as a priority in clinical practice rather than detection of SNP genotyping. Clinical trials registration: PROSPERO registration number CRD42022347907.
... A value of I 2 less than 25% was considered low heterogeneity, 26 to 50% was considered moderate heterogeneity, and greater than 50% was deemed high heterogeneity. 12,13 Subgroup analyses were done based on previous treatments to analyze the efficacy of adding bromocriptine to standard regimens. ...
Article
Full-text available
Introduction. There has been an increasing awareness of the effects of combining bromocriptine-QR with other medications for diabetes mellitus type 2. This study aimed to assess the efficacy and safety of bromocriptine-QR as an adjunctive therapy for patients with uncontrolled type 2 diabetes mellitus. Methodology. This systematic review is registered at the International Prospective Register of Systematic Reviews (CRD42022360326). Literature search was done via MEDLINE, NCBI, Google Scholar, Science Direct, Europe PMC and Cochrane Library databases. We included randomized controlled trials with participants 18 years old and above with uncontrolled type 2 diabetes mellitus. The primary outcome of interest is the efficacy and safety of bromocriptine-QR as an adjunctive therapy for glycemic control. Case reports, case series, reviews and animal studies were excluded. The risk of bias was reviewed using the Cochrane Risk of Bias tool. Meta-analysis was performed using Review Manager 5.4 and presented as a weighted mean difference and 95% confidence interval for changes from the baseline level. Results. Nine studies were included in the systematic review with a total of 2709 participants. The baseline HbA1c in the bromocriptine-QR group was 7.42% and 7.51% in the control group. The bromocriptine-QR group was favoured, outperforming the control group in terms of reducing hemoglobin A1c(HbA1c), with a statistically significant difference (weighted mean difference -0.6%; 95% CI [-0.83,-0.36]; p<0.00001). The most common side effects were nausea (33.75% vs 6.92%), fatigue (13.11% vs 5.94%), and headache (11.17% vs 6.87%). Conclusion. Administration of bromocriptine-QR at a dose range of 1.6 to 4.8 mg/day as an adjunctive therapy reduced HbA1c and FBG in patients with uncontrolled type 2 diabetes mellitus (T2DM). However, there were also statistically greater odds of the occurrence of adverse events such as nausea, vomiting, and headache compared to controls.
Article
BACKGROUND: Low back pain and sciatica caused by herniated lumbar discs (HLDs) are common complaints among patients visiting pain clinics. Among the various therapeutic methods, intradiscal ozone injections have emerged as an effective alternative or additional treatment option for HLDs. OBJECTIVE: This meta-analysis aimed to investigate the effectiveness of intradiscal ozone injections in the treatment of HLDs. METHODS: We searched the PubMed, Embase, Cochrane Library, and Scopus databases for relevant studies published until January 25, 2024. We included studies that investigated the efficacy of intradiscal ozone injections in patients with HLDs. We evaluated the methodological quality of individual studies using the Cochrane Collaboration tool. RESULTS: At ⩾ 6 months after treatment, the therapeutic effect of intradiscal ozone injections in patients with HLDs was greater than that of steroid injections (treatment success rate, 6 months: odds ratio = 3.95, 95% confidence interval [CI] [2.44, 6.39], P< 0.01) or conventional medications (changes in the Visual Analog Scale [VAS], 6 months: standardized mean difference [SMD] = 1.65, 95% CI [1.08, 2.22], P< 0.01; 12 months: SMD = 1.52, 95% CI [0.96, 2.08], P< 0.01) but similar to that of microdiscectomy (changes in VAS, 18 months: SMD =-0.05, 95% CI [-0.67, 0.57], P= 0.87). At < 6 months after treatment, the reduction in the VAS score after intradiscal ozone injections was higher than that after steroid injections (changes in VAS, 1 month: SMD = 2.53, 95% CI [1.84, 3.21], P< 0.01). CONCLUSION: Intradiscal ozone injections may be a useful therapeutic tool in patients with HLDs. Compared with other conventional treatment methods such as steroid injections and oral medications, intradiscal ozone injection has great long-term (⩾ 6 months) effectiveness.
Article
Investigations into the rivaroxaban response from the perspective of genetic variation have been relatively recent and wide in scope, whereas there is no consensus on the necessity of genetic testing of rivaroxaban. Thus, this systematic review aims to thoroughly evaluate the relationship between genetic polymorphisms and rivaroxaban outcomes. The PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Chinese databases were searched to 23 October 2022. We included cohort studies reporting the pharmacogenetic correlation of rivaroxaban. Outcomes measured included efficacy (all-cause mortality, thromboembolic events and coagulation-related tests), safety (major bleeding, clinically relevant non-major bleeding [CRNMB] and any hemorrhage), and pharmacokinetic outcomes. A narrative synthesis was performed to summarize findings from individual studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the reporting guideline for Synthesis Without Meta-Analysis. A total of 12 studies published between 2019 and 2022 involving 1364 patients were included. Ten, one, and six studies focused on the ABCB1, ABCG2, and CYP gene polymorphisms, respectively. Pharmacokinetic outcomes accounted for the majority of the outcomes reported (n = 11), followed by efficacy (n = 5) [including prothrombin time (PT) or international normalized ratio (n = 3), platelet inhibition rate (PIR) or platelet reactivity units (PRUs; n = 1), thromboembolic events (n = 1)], and safety (n = 5) [including major bleeding (n = 2), CRNMB (n = 2), any hemorrhage (n = 1)]. For ABCB1 gene polymorphism, the relationship between PT and ABCB1 rs1045642 was inconsistent across studies, however there was no pharmacogenetic relationship with other efficacy outcomes. Safety associations were found in ABCB1 rs4148738 and major bleeding, ABCB1 rs4148738 and CRNMB, ABCB1 rs1045642 and CRNMB, and ABCB1 rs2032582 and hemorrhage. Pharmacokinetic results were inconsistent among studies. For ABCG2 gene polymorphism, no correlation was observed between ABCG2 rs2231142 and dose-adjusted trough concentration (Cmin/D). For CYP gene polymorphisms, PIR or PRUs have a relationship with CYP2C19 rs12248560, however bleeding or pharmacokinetic effects did not show similar results. Currently available data are insufficient to confirm the relationship between clinical or pharmacokinetic outcomes of rivaroxaban and gene polymorphisms. Proactive strategies are advised as a priority in clinical practice rather than detection of SNP genotyping. PROSPERO registration number CRD42022347907.
Article
Full-text available
Article
Full-text available
Researchers carried out a randomised controlled trial to compare the effectiveness of cryotherapy with that of salicylic acid for treating plantar warts. Participants randomised to cryotherapy were treated with liquid nitrogen by a healthcare professional, with a maximum of four treatments, each two to three weeks apart. Participants randomised to 50% salicylic acid (Verrugon) treated themselves daily for a maximum of eight weeks. The primary outcome was complete clearance of plantar warts at 12 weeks.1The percentage of participants with complete clearance of plantar warts at 12 weeks was slightly higher in the salicylic acid group (17/119 (14.3%) v 15/110 (13.6%)), although the difference was not statistically significant (P=0.89).Which one of the following statistical tests would most likely have been used to compare the treatment groups with regard to the percentage of participants with complete clearance of plantar warts at 12 weeks?a) The χ2 testb) Fisher’s exact testc) McNemar’s testAnswersThe χ2 test (answer a) would most likely have been used to compare the treatment groups with regard to the percentage of participants with complete clearance of plantar warts at 12 weeks. The χ2 test is used to compare two independent groups in the proportion that possesses a particular characteristic. For the test to be valid, criteria described below must be met. The numbers of participants in each treatment group with and without complete clearance are shown in the contingency table⇓. The marginal totals are also shown, including the total sample size for each treatment group, plus total numbers with and without complete clearance.Comparison of treatments of cryotherapy and salicylic acid in complete clearance of plantar warts at 12 weeks
Article
Full-text available
To evaluate the effectiveness of multifactorial assessment and intervention programmes to prevent falls and injuries among older adults recruited to trials in primary care, community, or emergency care settings. Systematic review of randomised and quasi-randomised controlled trials, and meta-analysis. Six electronic databases (Medline, Embase, CENTRAL, CINAHL, PsycINFO, Social Science Citation Index) to 22 March 2007, reference lists of included studies, and previous reviews. Eligible studies were randomised or quasi-randomised trials that evaluated interventions to prevent falls that were based in emergency departments, primary care, or the community that assessed multiple risk factors for falling and provided or arranged for treatments to address these risk factors. Outcomes were number of fallers, fall related injuries, fall rate, death, admission to hospital, contacts with health services, move to institutional care, physical activity, and quality of life. Methodological quality assessment included allocation concealment, blinding, losses and exclusions, intention to treat analysis, and reliability of outcome measurement. 19 studies, of variable methodological quality, were included. The combined risk ratio for the number of fallers during follow-up among 18 trials was 0.91 (95% confidence interval 0.82 to 1.02) and for fall related injuries (eight trials) was 0.90 (0.68 to 1.20). No differences were found in admissions to hospital, emergency department attendance, death, or move to institutional care. Subgroup analyses found no evidence of different effects between interventions in different locations, populations selected for high risk of falls or unselected, and multidisciplinary teams including a doctor, but interventions that actively provide treatments may be more effective than those that provide only knowledge and referral. Evidence that multifactorial fall prevention programmes in primary care, community, or emergency care settings are effective in reducing the number of fallers or fall related injuries is limited. Data were insufficient to assess fall and injury rates.